BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Equibles//Investor Events//EN CALSCALE:GREGORIAN METHOD:PUBLISH NAME:Artelo Biosciences\, Inc. (ARTL) investor events X-WR-CALNAME:Artelo Biosciences\, Inc. (ARTL) investor events DESCRIPTION:Earnings calls and investor events for Artelo Biosciences\, Inc . (ARTL)\, from Equibles. X-WR-CALDESC:Earnings calls and investor events for Artelo Biosciences\, In c. (ARTL)\, from Equibles. REFRESH-INTERVAL;VALUE=DURATION:PT6H X-PUBLISHED-TTL:PT6H BEGIN:VEVENT UID:19054f54-f7e8-46d7-9d4e-e1f85c25625c@equibles.com DTSTAMP:20260617T191257Z DTSTART;VALUE=DATE:20260317 DTEND;VALUE=DATE:20260318 SEQUENCE:0 STATUS:CANCELLED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Earnings Call\, FY2025 Q4 DESCRIPTION:No call was held: the company published its results without one . END:VEVENT BEGIN:VEVENT UID:4ae85347-a83e-4ecd-a22e-a8e838789107@equibles.com DTSTAMP:20261003T042701Z DTSTART;VALUE=DATE:20260514 DTEND;VALUE=DATE:20260515 SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Earnings Call\, FY2026 Q1 DESCRIPTION:The start time has not been announced.\nWebcast: https://ir.art elobio.com/news-events/press-releases/detail/187/artelo-biosciences-provid es-business-update-outlining URL:https://equibles.com/stocks/artl/calls/2026-q1 END:VEVENT BEGIN:VEVENT UID:357f93c3-228e-48b5-b856-0c45f6f55323@equibles.com DTSTAMP:20260624T233126Z DTSTART;VALUE=DATE:20260601 DTEND;VALUE=DATE:20260602 SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Capital Markets Day: Investor Pres entation - June 2026 DESCRIPTION:Investor Presentation - June 2026\nThe start time has not been announced.\nWebcast: https://d1io3yog0oux5.cloudfront.net/_ae5bbf475b1c1dc cd94353c06e203dc0/artelobio/db/843/7665/pdf/Artelo+Biosciences+-+Investor+ Deck+%2801JUN2026.2%29.pdf END:VEVENT BEGIN:VEVENT UID:b2456b7a-0fb2-49c4-b2d7-8c3bdde13575@equibles.com DTSTAMP:20260715T031905Z DTSTART;VALUE=DATE:20260714 DTEND;VALUE=DATE:20260715 SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Annual General Meeting: Artelo Bio sciences Issues Reminder to Shareholders to Vote in Advance of Annual Meet ing on July 17\, 2026 DESCRIPTION:Artelo Biosciences Issues Reminder to Shareholders to Vote in A dvance of Annual Meeting on July 17\, 2026\nThe start time has not been an nounced.\nWebcast: https://ir.artelobio.com/news-events/press-releases/det ail/193/artelo-biosciences-issues-reminder-to-shareholders-to-vote END:VEVENT BEGIN:VEVENT UID:14f7deef-3cfb-45c0-bd5c-ea8476fbaedc@equibles.com DTSTAMP:20260624T233126Z DTSTART;VALUE=DATE:20260717 DTEND;VALUE=DATE:20260718 SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Annual General Meeting: 2026 Annua l Meeting of Stockholders DESCRIPTION:2026 Annual Meeting of Stockholders\nThe start time has not bee n announced.\nWebcast: https://event.webcasts.com/viewer/faq.jsp?mType=a&c losebtn=no&useHtml5Slide=true&ishtml5player=true END:VEVENT BEGIN:VEVENT UID:df9509f1-10c3-4375-888a-fe6f8274a726@equibles.com DTSTAMP:20261003T042701Z DTSTART:20260813T120000Z DTEND:20260813T130000Z SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Earnings Call\, FY2026 Q2 DESCRIPTION:Webcast: https://ir.artelobio.com/news-events/press-releases/de tail/197/artelo-biosciences-provides-business-update-and-reports URL:https://equibles.com/stocks/artl/calls/2026-q2 END:VEVENT BEGIN:VEVENT UID:4367ac07-0cb5-44d3-9ba7-2dc7bc86d6ed@equibles.com DTSTAMP:20260818T165831Z DTSTART;VALUE=DATE:20260817 DTEND;VALUE=DATE:20260818 SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Capital Markets Day: Investor Pres entation - August 2026 DESCRIPTION:Investor Presentation - August 2026\nThe start time has not bee n announced.\nWebcast: https://d1io3yog0oux5.cloudfront.net/_75f1b7e7e9466 4b9e1f26910ea670d3c/artelobio/db/843/7669/pdf/Artelo+Biosciences+-+Investo r+Deck+%2817AUG2027%29.2.pdf END:VEVENT BEGIN:VEVENT UID:f5fca2fc-1727-4ff0-8bcc-bc13b8973de0@equibles.com DTSTAMP:20260902T051337Z DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20260902 SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Capital Markets Day: Investor Pres entation - September 2026 DESCRIPTION:Investor Presentation - September 2026\nThe start time has not been announced.\nWebcast: https://d1io3yog0oux5.cloudfront.net/_5a67b55ea5 99a5d0329a6a29c338abf2/artelobio/db/843/7670/pdf/Artelo+Biosciences+-+Inve stor+Deck+%2801SEP2026%29.pdf END:VEVENT BEGIN:VEVENT UID:e6940a2b-cad3-4dd9-b42f-9c1c716bc428@equibles.com DTSTAMP:20260908T172905Z DTSTART:20260908T130000Z DTEND:20260908T140000Z SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Conference: Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference DESCRIPTION:Artelo Biosciences to Present at the H.C. Wainwright 28th Annua l Global Investment Conference\nWebcast: https://ir.artelobio.com/news-eve nts/press-releases/detail/201/artelo-biosciences-to-present-at-the-h-c-wai nwright-28th END:VEVENT BEGIN:VEVENT UID:d4d5d68b-5e72-4bdc-b70c-fc9d2fb37e10@equibles.com DTSTAMP:20260908T172905Z DTSTART:20260911T110000Z DTEND:20260911T120000Z SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Conference: H.C. Wainwright 28th A nnual Global Investment Conference DESCRIPTION:H.C. Wainwright 28th Annual Global Investment Conference\nWebca st: https://ir.artelobio.com/news-events/ir-calendar/detail/20260911-h-c-w ainwright-28th-annual-global-investment-conference END:VEVENT BEGIN:VEVENT UID:a0cba6ac-c260-4010-b4d3-55aa5e3a6b8a@equibles.com DTSTAMP:20261008T023047Z DTSTART:20261007T124800Z DTEND:20261007T134800Z SEQUENCE:0 STATUS:CONFIRMED TRANSP:TRANSPARENT SUMMARY:Artelo Biosciences\, Inc. (ARTL) Investor Update: Artelo Bioscience s Selected for its First-Ever Company Presentation at BIO-Europe 2026 to S howcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhib itor Platform DESCRIPTION:Artelo Biosciences Selected for its First-Ever Company Presenta tion at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potent ial of its Novel FABP5 Inhibitor Platform\nWebcast: https://ir.artelobio.c om/news-events/press-releases/detail/204/artelo-biosciences-selected-for-i ts-first-ever-company END:VEVENT END:VCALENDAR